A new skin patch to help prevent relapse in opioid addiction
Naltrexone Transdermal Patch - An Accessible, Patient-Focused Option to Treat OUD Relapse
['FUNDING_OTHER'] · LIBERO PHARMA LIMITED · NIH-10708991
This study is testing a new skin patch that delivers naltrexone to help people with Opioid Use Disorder stay on track and avoid relapse, making treatment easier and more convenient than current options like injections or pills.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LIBERO PHARMA LIMITED (nih funded) |
| Locations | 1 site (EDINBURGH, UNITED KINGDOM) |
| Trial ID | NIH-10708991 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a transdermal patch that delivers naltrexone, a medication used to prevent relapse in individuals with Opioid Use Disorder (OUD). The patch aims to provide a more accessible and user-friendly alternative to current treatment options, which often involve injections or oral medications that can be difficult for patients to adhere to. By optimizing the delivery of naltrexone through a skin patch, the research seeks to improve treatment outcomes and reduce the risk of overdose. Patients will be monitored for their response to the patch and its effectiveness in preventing cravings and relapse.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Opioid Use Disorder who are at risk of relapse.
Not a fit: Patients who are not struggling with opioid addiction or those who have not been diagnosed with Opioid Use Disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more convenient and effective treatment option for individuals struggling with opioid addiction, potentially reducing relapse rates.
How similar studies have performed: While the approach of using a transdermal patch for medication delivery is not widely tested in this context, similar methods have shown promise in other areas of drug delivery and addiction treatment.
Where this research is happening
EDINBURGH, UNITED KINGDOM
- LIBERO PHARMA LIMITED — EDINBURGH, UNITED KINGDOM (ACTIVE)
Researchers
- Principal investigator: GARDINER, ANDREW — LIBERO PHARMA LIMITED
- Study coordinator: GARDINER, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.